Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Garrett Wirth

Plastic Surgery Newport Beach, CA Medical Doctor

NPI 1871605386 CMS profile 221320

1401 Avocado Ave Ste 810, Newport Beach, CA 92660

Open in the dashboard

General payments

$361,705

287 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Garrett Wirth of Newport Beach, CA is reported in the CMS Open Payments database as having received $361,705 across 287 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,803 19
2024 General $39,494 57
2023 General $97,647 32
2022 General $44,944 50
2021 General $1,699 30
2020 General $18,956 19
2019 General $145,162 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Garrett Wirth
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Garrett Wirth were reported at $13,803. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Garrett Wirth Plastic Surgery median Middle half National median
2019 $145,162 $371 $122–$1,483 $163
2020 $18,956 $158 $52–$438 $114
2021 $1,699 $249 $87–$752 $132
2022 $44,944 $274 $102–$793 $149
2023 $97,647 $299 $113–$891 $160
2024 $39,494 $361 $124–$1,062 $164
2025 $13,803 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. KCI USA, Inc $288,560 131 payments
  2. Solventum Corporation $50,111 24 payments
  3. Musculoskeletal Transplant Foundation Inc. $17,218 18 payments
  4. Mentor Worldwide LLC $1,665 29 payments
  5. Sientra, Inc. $998 12 payments
  6. AbbVie, Inc. $707 27 payments
  7. Allergan Inc. $412 18 payments
  8. Organogenesis Inc. $298 3 payments
  9. Davol Inc. $227 4 payments
  10. Smith+Nephew, Inc. $170 3 payments
  11. Other $1,337 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $145,130 25 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $66,320 1 payment
  3. Travel and Lodging $62,096 72 payments
  4. Consulting Fee $60,294 11 payments
  5. Education $15,930 4 payments
  6. Food and Beverage $11,935 174 payments
Products named General payments · program years 2019–2025
  1. PREVENA Negative Pressure Systems & Dressings $148,582 40 payments
  2. V.A.C. VERAFLO CLEANSE CHOICE $137,166 21 payments
  3. V.A.C. VERAFLO $94,850 33 payments
  4. 3M Cavilon $91,673 6 payments
  5. VAC VERAFLO $60,934 42 payments
  6. PREVENA Non-Covered $56,446 42 payments
  7. V.A.C. DERMATAC $45,482 12 payments
  8. VAC VERAFLO CLEANSE CHOICE $34,663 12 payments
  9. PROMOGRAN PRISMA $27,771 10 payments
  10. PREVENA RESTOR BELLAFORM $18,188 11 payments
  11. Other $65,339 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$19,226

Medicare's payments for the services billed

Medicare patients

28

Average age 72

Services billed

117

16 women, 12 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 61%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $140
$140 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record